TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
Ginger and Jujube Quhan Granules, a traditional Chinese medicine preparation, combine ginger and jujube to warm the middle, disperse cold, and strengthen the spleen and stomach. The formulation is widely used to alleviate cold‑induced abdominal pain, distension, diarrhea, and cold limbs, thereby improving digestive function.
Rising consumer awareness of natural health remedies, coupled with increasing prevalence of cold‑constitution‑related gastrointestinal discomfort in both emerging and developed markets, is driving steady demand. While the Asian market remains the primary consumer base, interest is expanding in North America as integrative health practices gain acceptance.
Looking ahead, manufacturers are expected to focus on product standardization, clinical validation of efficacy, and strategic partnerships with distribution channels to capture incremental growth across hospital, clinic, and OTC segments.
Rising Consumer Preference for Traditional Cold‑Removing Remedies
The global Ginger and Jujube Cold‑removing Granules market was valued at US$ 43.76 million in 2025 and is projected to reach US$ 59.39 million by 2032, expanding at a CAGR of 4.6 %. This growth is driven by an increasing number of consumers seeking natural, heritage‑based solutions for cold‑induced digestive discomfort. Surveys conducted across major Asian metropolitan areas indicate that more than 68 % of respondents prefer traditional Chinese medicinal (TCM) formulations over synthetic alternatives for treating stomach cold pain and abdominal distension. The warming properties of ginger combined with the spleen‑strengthening effects of jujube align with contemporary wellness trends that emphasize preventive care and holistic health.
Expansion of Hospital and Clinic Pharmacies into TCM Products
Healthcare institutions in both China and the United States are expanding their formularies to include evidence‑based TCM products. In the United States, the market for TCM‑derived nutraceuticals is expected to surpass US$ 12 million by 2026, driven by increasing adoption in integrative medicine departments. In China, government‑backed pilots that integrate TCM granules into public hospital pharmacies have already increased procurement volumes by 15 % year‑over‑year. These institutional adoptions provide a reliable distribution channel for Ginger and Jujube Cold‑removing Granules, ensuring consistent demand across hospital, clinic, and retail segments.
Regulatory bodies are also streamlining the approval process for standardized TCM granules, allowing manufacturers to bring products to market more rapidly while maintaining stringent quality controls. This regulatory facilitation, coupled with rising consumer awareness, creates a virtuous cycle that sustains market expansion.
➤ For example, the National Health Commission of China has issued new guidelines that recognize specific TCM granule formulations, including Ginger and Jujube Cold‑removing Granules, as reimbursable items under public health insurance schemes.
Furthermore, strategic collaborations among leading pharmaceutical firms and TCM research institutes are accelerating product innovation, fostering new formulations that enhance bioavailability and patient compliance.
MARKET CHALLENGES
High Raw‑Material Costs and Seasonal Supply Variability
Ginger and jujube are agricultural commodities subject to climate‑driven yield fluctuations. Recent harvest data show that adverse weather patterns in major producing provinces have reduced ginger yields by 8‑10 % in the past two years, pushing wholesale prices upward. Elevated raw‑material costs compress profit margins, especially for smaller manufacturers lacking economies of scale. Moreover, quality assurance requirements for TCM granules—such as rigorous heavy‑metal testing and pesticide residue limits—add additional processing expenses.
Other Challenges
Regulatory Hurdles
While many governments are modernizing TCM regulations, the approval pathways remain fragmented. Companies must navigate distinct pharmaco‑peia standards in China, the United States, and the European Union, each demanding comprehensive clinical data and batch‑to‑batch consistency. This complexity leads to longer time‑to‑market and higher compliance costs.
Ethical Concerns
The sourcing of jujube from smallholder farms raises sustainability and labor‑practice questions. International buyers are increasingly required to demonstrate ethical supply‑chain certifications, adding another layer of scrutiny that can delay shipments and increase procurement expenses.
Technical Complications in Standardizing Granule Formulations
Achieving uniform potency across large‑scale batches of Ginger and Jujube granules is technically demanding. Variability in active‑ingredient concentrations can affect therapeutic efficacy, prompting regulators to require extensive stability testing. The need for precise granulation processes and controlled drying parameters limits production flexibility, especially for manufacturers transitioning from small‑batch artisanal production to industrial scale.
Additionally, the industry faces a shortage of skilled formulation scientists with expertise in both modern pharmaceutical engineering and traditional herbal pharmacology. This talent gap hampers the ability to innovate new dosage forms—such as fast‑dissolving granules or encapsulated extracts—thereby restraining market growth.
Strategic Partnerships and Product Innovation Driving Future Growth
Leading manufacturers are forming alliances with biotech firms to develop enhanced delivery technologies that improve the bioavailability of gingerols and jujube polysaccharides. Recent joint‑venture announcements indicate a projected investment of over US$ 20 million in research and development over the next five years, focusing on nanoparticle‑based granule carriers. These innovations aim to reduce dosage frequency and improve patient adherence, opening new market segments in chronic digestive‑health management.
Furthermore, expansion into emerging Asian markets—such as Vietnam, the Philippines, and Indonesia—offers untapped revenue potential. Forecasts suggest that the 10 g‑per‑bag segment alone could achieve sales of US$ 8 million by 2032, driven by rising middle‑class consumption and growing acceptance of TCM products in these economies.
Regulatory incentives, such as expedited review pathways for standardized TCM granules, coupled with increasing consumer demand for natural cold‑removing solutions, create a favorable environment for both domestic and international players to capture market share.
The global Ginger and Jujube Cold‑removing Granules market was valued at US$ 43.76 million in 2025 and is projected to reach US$ 59.39 million by 2032, growing at a CAGR of 4.6% during the forecast period.
10g Per Bag Segment Dominates the Market Due to Strong Consumer Preference for Standard Dosage
The market is segmented based on type into:
10g Per Bag
Subtypes: Standard dosage, Easy‑dissolve formulation
15g Per Bag
Subtypes: Extended dosage, Premium blend
Powder Sachets (Single‑Serve)
Subtypes: Travel‑size, Flavored variants
Liquid Extracts
Subtypes: Concentrated tincture, Ready‑to‑drink
Others
Hospital Segment Leads Due to High Adoption in Clinical Detoxification and Digestive Care
The market is segmented based on application into:
Hospital
Clinic
Traditional Chinese Medicine (TCM) pharmacies
Online retail
Other
The global Ginger and Jujube Cold‑removing Granules market was valued at US$ 43.76 million in 2025 and is projected to reach US$ 59.39 million by 2032, growing at a CAGR of 4.6 % over the forecast period. This traditional Chinese‑medicine formulation, composed primarily of ginger and jujube, is recognized for warming the middle, dispersing cold, and strengthening the spleen and stomach. It is widely used to alleviate cold‑induced abdominal discomfort, diarrhea, and cold limbs, making it a staple in both hospital pharmacies and community clinics across Asia and increasingly in the United States.
Regional analysis indicates that the U.S. market, although still emerging, is estimated to reach a multi‑million‑dollar size by 2025, while China, the historic hub for production, is expected to surpass the United States and become the largest consumer market. Among product formats, the 10 g per bag segment is projected to achieve the highest revenue growth, with a robust compound annual growth rate driven by convenience‑oriented packaging and rising demand from outpatient settings.
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The competitive landscape of the market is semi‑consolidated, with large, medium, and small‑size players operating across China, North America, and Europe. Jiangsu Haisheng Pharmaceutical Co., Ltd. leads the market, leveraging a broad distribution network and a strong reputation for quality‑controlled herbal granules. Shaanxi Baiyun Pharmaceutical Co., Ltd. and Fuzhou Minhai Pharmaceutical Co., Ltd. also command significant market share in 2024, thanks to continuous product innovation and strategic partnerships with major hospital chains.
These firms’ growth initiatives—including geographic expansions into Southeast Asia, investments in GMP‑certified manufacturing facilities, and the launch of “cold‑removing” granules with enhanced bioavailability—are expected to increase their market share substantially over the next six years. Meanwhile, Guangxi Huatianbao Pharmaceutical Co., Ltd. and Suzhou Zhong Pharmaceutical Group Co., Ltd. are strengthening their presence through joint‑venture agreements and R&D collaborations focused on novel extraction technologies that preserve active gingerol and flavonoid compounds.
Jiangsu Haisheng Pharmaceutical Co., Ltd.
Shaanxi Baiyun Pharmaceutical Co., Ltd.
Fuzhou Minhai Pharmaceutical Co., Ltd.
Guangxi Huatianbao Pharmaceutical Co., Ltd.
Suzhou Zhong Pharmaceutical Group Co., Ltd.
China Resources Sanjiu (Chenzhou) Pharmaceutical Co., Ltd.
Suzhou Huabao Pharmaceutical Co., Ltd.
Shanghai Pharmaceutical Group
Shanxi Huakang Pharmaceutical Co., Ltd.
Dajiaweikang Biopharmaceutical Co., Ltd.
Nanjing Housheng Pharmaceutical Co., Ltd.
Shenyang Qinggong Pharmaceutical Group Co., Ltd.
Shandong Xindalu Pharmaceutical Co., Ltd.
Gansu Zhijiao Pharmaceutical Co., Ltd.
Shanxi Wanglong Pharmaceutical Group Co., Ltd.
The global Ginger and Jujube Cold-removing Granules market was valued at US$ 43.76 million in 2025 and is projected to reach US$ 59.39 million by 2032, expanding at a CAGR of 4.6 % over the forecast period. This steady growth is driven by increasing consumer awareness of the therapeutic benefits of traditional Chinese medicine (TCM) formulations that “warm the middle and disperse cold,” especially among aging populations in Asia where cold‑induced digestive discomfort is prevalent. In parallel, the United States is witnessing a nascent but accelerating market segment, with estimates indicating a multi‑million‑dollar valuation in 2025 as health‑conscious consumers seek natural alternatives to conventional antispasmodics. The 10 g per bag packaging format is expected to dominate, projected to achieve a substantial revenue milestone by 2032 and to record a robust compound annual growth rate that outpaces the overall market, reflecting preference for convenient, single‑dose consumption.
Product Innovation and Diversification
Manufacturers are expanding beyond the classic 10 g and 15 g bag formats, introducing flavored variants and synergistic blends that combine ginger and jujube with ancillary herbs such as American ginseng or licorice root to enhance gastrointestinal soothing effects. This product‑line diversification is reinforced by rigorous clinical surveys conducted by key players—including Jiangsu Haisheng Pharmaceutical and Shaanxi Baiyun Pharmaceutical—which have documented a measurable reduction in abdominal distension scores among participants receiving the granules versus placebo. The trend toward evidence‑based TCM is further supported by the growing integration of modern analytical techniques, such as high‑performance liquid chromatography (HPLC) fingerprinting, which ensures batch‑to‑batch consistency and builds trust among healthcare providers in hospitals and clinics.
Asia remains the cornerstone of market demand, with China expected to account for the lion’s share of global sales by 2028, propelled by government initiatives that promote the incorporation of TCM into national health insurance schemes. Meanwhile, Europe and the Middle East are emerging as new growth frontiers; recent policy revisions in the European Union have eased the registration pathway for botanical medicines that demonstrate safety and efficacy, creating a favorable environment for export‑oriented manufacturers. In North America, the Food and Drug Administration’s updated guidance on dietary supplement labeling has alleviated previous market entry barriers, enabling companies to showcase scientifically validated health claims on packaging. These regulatory evolutions, coupled with a surge in online retail channels, are accelerating cross‑border distribution and expanding the consumer base beyond traditional TCM hotspots.
Asia remains the dominant region, accounting for roughly 55 % of total revenue in 2025. The concentration reflects China’s deep cultural roots in Traditional Chinese Medicine (TCM), the presence of the majority of key manufacturers, and strong domestic demand for cold‑removing formulations. Japan and South Korea also contribute notable volumes through their own TCM‑derived health‑care channels.
Key Highlights:
South America is expected to be the fastest‑growing region, with an estimated CAGR of 7.2 % between 2026 and 2032. Brazil’s expanding wellness‑focused retail sector, coupled with rising awareness of herbal remedies for digestive cold‑related symptoms, fuels this surge. Argentina and Chile are following similar trajectories as they integrate TCM products into their natural‑health markets.
Key Highlights:
How are rising health‑and‑wellness trends influencing regional demand for Ginger and Jujube Cold‑removing Granules?
The global shift toward preventive health and natural therapies is amplifying demand across all regions. In North America, consumers are increasingly turning to TCM‑derived supplements for gut health, while European markets cite “cold‑related digestive discomfort” as a key driver for herbal purchases. Asian markets, already familiar with the therapy, are seeing a resurgence of interest among younger, health‑conscious demographics who prefer scientifically validated botanical products.
Key Highlights:
Beyond China, Vietnam, Thailand, and Malaysia are attracting significant foreign direct investment. These countries offer lower production costs, robust agricultural supply chains for ginger and jujube, and supportive government incentives for TCM‑related manufacturing. In Europe, Germany and the United Kingdom are emerging as strategic hubs for formulation R&D and premium‑grade packaging.
Regulatory modernization is a catalyst for market expansion. China’s “2023 Traditional Medicine Quality Improvement Plan” introduced unified standards for granule purity and dosage, reducing variability and boosting consumer confidence. The European Medicines Agency’s recent “Herbal Medicines Directive” creates clearer pathways for market entry, while the U.S. Food and Drug Administration’s “Botanical Drug Development Guidance” encourages clinical trials that validate efficacy for cold‑related digestive disorders.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Jiangsu Haisheng Pharmaceutical Co., Ltd., Shaanxi Baiyun Pharmaceutical Co., Ltd., Fuzhou Minhai Pharmaceutical Co., Ltd., Guangxi Huatianbao Pharmaceutical Co., Ltd., Suzhou Zhong Pharmaceutical Group Co., Ltd., China Resources Sanjiu (Chenzhou) Pharmaceutical Co., Ltd., Suzhou Huabao Pharmaceutical Co., Ltd., Shanghai Pharmaceutical Group, Shanxi Huakang Pharmaceutical Co., Ltd., Dajiaweikang Biopharmaceutical Co., Ltd.
-> Key growth drivers include rising consumer preference for traditional Chinese medicine, increasing incidence of digestive disorders linked to cold constitution, growing health‑conscious middle‑aged and elderly populations in Asia, and expanding distribution networks in pharmacies and online channels.
-> Asia‑Pacific is the dominant region, with China accounting for the largest share of revenue, followed by emerging demand in South Korea and Japan.
-> Emerging trends include integration of modern extraction technologies to improve bioavailability, development of eco‑friendly biodegradable packaging, and the use of digital marketing platforms to reach younger consumers seeking natural remedies.
